- Home
- SOL vs ARMP Comparison
SOL vs ARMP Comparison
Compare SOL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ARMP
- Stock Information
- Founded
- SOL 2005
- ARMP N/A
- Country
- SOL United States
- ARMP United States
- Employees
- SOL N/A
- ARMP N/A
- Industry
- SOL Semiconductors
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOL Technology
- ARMP Health Care
- Exchange
- SOL Nasdaq
- ARMP Nasdaq
- Market Cap
- SOL 89.7M
- ARMP 80.0M
- IPO Year
- SOL 2008
- ARMP N/A
- Fundamental
- Price
- SOL $1.66
- ARMP $2.11
- Analyst Decision
- SOL Buy
- ARMP Strong Buy
- Analyst Count
- SOL 3
- ARMP 1
- Target Price
- SOL $3.83
- ARMP $7.00
- AVG Volume (30 Days)
- SOL 181.6K
- ARMP 8.1K
- Earning Date
- SOL 03-27-2025
- ARMP 03-20-2025
- Dividend Yield
- SOL N/A
- ARMP N/A
- EPS Growth
- SOL N/A
- ARMP N/A
- EPS
- SOL N/A
- ARMP N/A
- Revenue
- SOL $102,489,000.00
- ARMP $5,467,000.00
- Revenue This Year
- SOL N/A
- ARMP $23.87
- Revenue Next Year
- SOL $47.66
- ARMP N/A
- P/E Ratio
- SOL N/A
- ARMP N/A
- Revenue Growth
- SOL 25.98
- ARMP 34.92
- 52 Week Low
- SOL $1.41
- ARMP $1.80
- 52 Week High
- SOL $3.00
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- SOL 36.27
- ARMP 56.44
- Support Level
- SOL $1.67
- ARMP $1.85
- Resistance Level
- SOL $1.79
- ARMP $2.08
- Average True Range (ATR)
- SOL 0.08
- ARMP 0.12
- MACD
- SOL -0.00
- ARMP 0.00
- Stochastic Oscillator
- SOL 18.52
- ARMP 56.67
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.